Evaluation of CD133 and CD56/NCAM expression in Wilms tumor and their association with prognostic factors

Objective To validate certain markers for detecting cancer stem cell populations and to evaluate their clinical significance in Wilms tumor (WT) Materials and MethodsImmunohistochemical study for CD133 and CD56/NCAM was performed on fortysix cases of WT that were diagnosed between 1999 and 2015 and the association of these markers with the survival and prognostic factors were analyzed. Results Thirty-four (73.9%) of WTs were positive for CD133 and thirty-nine (84.8%) were positive for CD56/NCAM. A significant positive correlation was found between expression of CD133 and CD56/NCAM and the National Wilms Tumor Stage (NWTS) and death. Moreover, overall survival time was significantly correlated with CD133 and CD56/NCAM H-score, NWTS stage, and death. Conclusions It seems that CD133 and CD56/NCAM expressions can be used as strong prognostic parameters for survival of patients with WT and can be used to predict WT patients’ stage. Moreover, their targeted therapies can abolish cancer stem cells in children with difficult-to-treat or recurrent tumors.

Keywords:

Wilms tumor , immunohistochemistry , Neural Cell Adhesion Molecules , CD133